A Phase 1 interventional study of Epanutin Infatabs (Phenytoin) and Dilantin Infatabs (Phenytoin) in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Seizures by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Seizures · Viatris Inc..
Among the 12 studies in Seizures by Viatris Inc., this one is the 12th largest by enrollment, is one of 3 that started in 2011, is the only one in phase 1, and was the 9th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →None of the 12 studies in Seizures by Viatris Inc. is open now. The open studies under Seizures, anywhere →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 261 across the 12 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Seizures by Viatris Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study, the bioequivalence of Epanutin Infatabs® 50 mg (sourced from Germany) and Dilantin Infatabs® 50 mg (sourced from Australia) will be assessed. This is intended to be a pivotal bioequivalence study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)
Drug: Epanutin Infatabs (Phenytoin)
Dilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)
Drug: Dilantin Infatabs (Phenytoin)
Chewable Tablet, 50 mg, Single dose
Chewable Tablet, 50 mg, Single dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, and 72 hours (hrs) post-dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Extrapolated Area Under the Curve (AUC Percent [%] Extrap)
AUC%extrap is the percentage of AUC \[0-∞\] obtained by forward extrapolation. It is calculated as (AUC \[0-∞\] minus AUClast)\*100/ AUC \[0-∞\], where AUC \[0-∞\] = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUClast is area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Plasma Decay Half Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
| Milestone | Epanutin Infatabs 50 mg First, Then Dilantin Infatabs 50 mg | Dilantin Infatabs 50 mg First, Then Epanutin Infatabs 50 mg |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 11 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Epanutin Infatabs 50 mg First, Then Dilantin Infatabs 50 mg | Dilantin Infatabs 50 mg First, Then Epanutin Infatabs 50 mg |
|---|---|---|
| Started | 13 | 11 |
| Completed | 13 | 11 |
| Not completed | 0 | 0 |
| Milestone | Epanutin Infatabs 50 mg First, Then Dilantin Infatabs 50 mg | Dilantin Infatabs 50 mg First, Then Epanutin Infatabs 50 mg |
|---|---|---|
| Started | 13 | 11 |
| Completed | 13 | 11 |
| Not completed | 0 | 0 |
Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).
| ng*hr/mL | Epanutin Infatabs 50 mg | Dilantin Infatabs 50 mg |
|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | 21380.0 ± 6043.0 | 21370.0 ± 5571.2 |
| ng/mL | Epanutin Infatabs 50 mg | Dilantin Infatabs 50 mg |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 952.10 ± 229.25 | 976.50 ± 214.78 |
AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).
| ng*hr/mL | Epanutin Infatabs 50 mg | Dilantin Infatabs 50 mg |
|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞]) | 21730.0 ± 6345.9 | 21740.0 ± 5816.7 |
AUC%extrap is the percentage of AUC \[0-∞\] obtained by forward extrapolation. It is calculated as (AUC \[0-∞\] minus AUClast)\*100/ AUC \[0-∞\], where AUC \[0-∞\] = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUClast is area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.
| Percent AUC | Epanutin Infatabs 50 mg | Dilantin Infatabs 50 mg |
|---|---|---|
| Extrapolated Area Under the Curve (AUC Percent [%] Extrap) | 3.321 ± 4.884 | 3.198 ± 4.805 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | Epanutin Infatabs 50 mg | Dilantin Infatabs 50 mg |
|---|---|---|
| Plasma Decay Half Life (t1/2) | 14.380 ± 3.247 | 14.970 ± 4.777 |
| hr | Epanutin Infatabs 50 mg | Dilantin Infatabs 50 mg |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 3.51 (1.00 to 5.00) | 4.00 (1.00 to 6.00) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epanutin Infatabs 50 mg | — | 0/24 (0%) | 4/24 (16.7%) |
| Dilantin Infatabs 50 mg | — | 0/26 (0%) | 2/26 (7.7%) |
| Event | Epanutin Infatabs 50 mg | Dilantin Infatabs 50 mg |
|---|---|---|
| HeadacheNervous system disorders | 2/24 | 0/26 |
| Upper respiratory tract infectionInfections and infestations | 1/24 | 1/26 |
| DizzinessNervous system disorders | 1/24 | 0/26 |
| RashSkin and subcutaneous tissue disorders | 0/24 | 1/26 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 31.8 ± 8.3 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 1 |
| Male | 25 |
The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phenytoin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →